
Eisai’s cancer drug Halaven met its primary endpoint and demonstrated overall survival benefit in two distinct solid tumour types in …
Eisai’s planned job cuts will fall heaviest on its US operations, where 20% of the workforce will be let go …
Eisai has published further details of a phase III trial of its first-in-class chemotherapy drug Halaven ahead of its hoped-for …
A new cancer drug developed by Japanese pharma company Eisai has shown promise in increasing overall survival rates in heavily …
Japanese drugmaker Eisai has opened a 65,000-sq.ft. facility at Research Triangle Park in North Carolina, USA, which will serve as …